See also this year's filing and all EDGAR filings for this company.
PDF Report 0001034842_2020_RIGEL_PHARMACEUTICALS_INC.pdf
Logs
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001034842, RIGEL PHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 119,005,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 2,159,000 |
| 3 | remainder_Assets | 26,405,000 |
| 4 | LiabilitiesCurrent | 58,212,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 906,000 |
| 8 | SellingGeneralAndAdministrativeExpense | 74,588,000 |
| 9 | ResearchAndDevelopmentExpense | 52,885,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 59,288,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 2,244,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 147,569,000 |
| 1 | Liabilities | 58,212,000 |
| 2 | Expenses | 128,379,000 |
| 3 | Revenues | 59,288,000 |
| 4 | StockholdersEquity | 89,357,000 |
| 5 | NetIncome | -69,091,000 |
| 6 | ComprehensiveNetIncome | -67,969,000 |
| 7 | BaseVar | 197,846,000 |
| 8 | EconomicCapitalRatio | 0.833 |
Edgar->Model Mapping
Feature Distribution
Change over Time
